Skip to main content
. 2020 Aug 11;10(8):580. doi: 10.3390/diagnostics10080580

Figure 4.

Figure 4

Immunostaining results. (A,B) The carcinomatous component was highlighted using (A) cytokeratin 7 and (B) epithelial membrane antigens. (C) The sarcomatous component reacted with vimentin. (D,E) In high-power view, the carcinomatous and sarcomatous components showed mutually exclusive immunoreactivity to (D) pan-cytokeratin and (E) vimentin, respectively. Staining method: (AE), polymer method. Original magnification: (AC), 40×; (D,E), 200×.